Fas receptor is required for estrogen deficiency-induced bone loss in mice

Laboratory Investigation

Volumn 90, Issue 3, 2010, Pages 402-413

  Kovacic, Natasa ^a   Grcevic, Danka ^a   Katavic, Vedran ^a   Lukic, Ivan Kresimir ^b   Grubisic, Vladimir ^a   Mihovilovic, Karlo ^a   Cvija, Hrvoje ^a   Croucher, Peter Ian ^c   Marusic, Ana ^a,d  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b Biosistemi   (Croatia)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF SPLIT   (Croatia)

Author keywords

Apoptosis; CD95; Knockout mice; Osteoblast; Osteoclast; Osteoporosis

Indexed keywords

ESTRADIOL; ESTROGEN; FAS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; ESTROGEN DEFICIENCY; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELL DIFFERENTIATION; CELL LINEAGE; CELLS, CULTURED; ESTROGENS; FAS LIGAND PROTEIN; FEMALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; OVARIECTOMY; SIGNAL TRANSDUCTION;

EID: 77649101502     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.144     Document Type: Article

References (36)

1. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992;257: 88-91.
2. Kousteni S, Chen JR, Bellido T, et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 2002;298:843-846.
3. Tomkinson A, Reeve J, Shaw RW, et al. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 1997;82:3128-3135.
4. Denault JB, Salvesen GS. Caspases: keys in the ignition of cell death. Chem Rev 2002;102:4489-4500.
5. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005;115:1-20.
6. Siegel RM, Chan FK, Chun HJ, et al. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000;1:469-474.
7. Ishimaru N, Saegusa K, Yanagi K, et al. Estrogen deficiency accelerates autoimmune exocrinopathy in murine Sjogren's syndrome through fas-mediated apoptosis. Am J Pathol 1999;155:173-181.
8. Jaita G, Candolfi M, Zaldivar V, et al. Estrogens up-regulate the Fas/FasL apoptotic pathway in lactotropes. Endocrinology 2005;146:4737-4744.
9. Suzuki A, Enari M, Eguchi Y, et al. Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle. EMBO J 1996;15:211-215.
10. Garcia-Moreno C, Catalan MP, Ortiz A, et al. Modulation of survival in osteoblasts from postmenopausal women. Bone 2004;35:170-177.
11. Kovacic N, Lukic IK, Grcevic D, et al. The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis. J Immunol 2007;178:3379-3389.
12. Adachi M, Suematsu S, Kondo T, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995;11:294-300.
13. Katavic V, Lukic IK, Kovacic N, et al. Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. J Immunol 2003;170:1540-1547.
14. Grcevic D, Lee SK, Marusic A, et al. Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. J Immunol 2000;165: 4231-4238.
15. Stahlberg A, Hakansson J, Xian X, et al. Advanced quantitative realtime PCR in clinical diagnostics and cDNA microarray validation. 1st European Conference in Functional Genomics and Diseases. Prague, Czech Republic, 2003.
16. University of Connecticut Health Center. Genome anatomy project for the osteoprogenitor lineage. Available from: http:// skeletalbiology.uchc.edu/30- ResearchProgram/304-gap/index.htm.
17. Bu R, Borysenko CW, Li Y, et al. Expression and function of TNF-family proteins and receptors in human osteoblasts. Bone 2003;33:760-770.
18. Hatakeyama S, Tomichi N, Ohara-Nemoto Y, et al. The immunohistochemical localization of Fas and Fas ligand in jaw bone and tooth germ of human fetuses. Calcif Tissue Int 2000;66:330-337.
19. Ogawa Y, Ohtsuki M, Uzuki M, et al. Suppression of osteoclastogenesis in rheumatoid arthritis by induction of apoptosis in activated CD4+ T cells. Arthritis Rheum 2003;48:3350-3358.
20. Wu X, McKenna MA, Feng X, et al. Osteoclast apoptosis: the role of Fas in vivo and in vitro. Endocrinology 2003;144:5545-5555.
21. Nagata S, Golstein P. The Fas death factor. Science 1995;267: 1449-1456.
22. Eischen CM, Schilling JD, Lynch DH, et al. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996;156:2693-2699.
23. Kiener PA, Davis PM, Rankin BM, et al. Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol 1997;159:1594-1598.
24. De Maria R, Testa U, Luchetti L, et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 1999;93: 796-803.
25. Krum SA, Miranda-Carboni GA, Hauschka PV, et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008;27:535-545.
26. Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007;130:811-823.
27. Kameda T, Mano H, Yuasa T, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 1997;186:489-495.
28. Cenci S, Weitzmann MN, Roggia C, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000;106:1229-1237.
29. Park H, Jung YK, Park OJ, et al. Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. J Immunol 2005;175:7193-7201.
30. Jilka RL, Takahashi K, Munshi M, et al. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest 1998;101:1942-1950.
31. Kawakami A, Eguchi K, Matsuoka N, et al. Fas and Fas ligand interaction is necessary for human osteoblast apoptosis. J Bone Miner Res 1997;12:1637-1646.
32. Tsuboi M, Kawakami A, Nakashima T, et al. Tumor necrosis factor-alpha and interleukin-1beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med 1999;134:222-231.
33. Kuo PL. Myricetin inhibits the induction of anti-Fas IgM-, tumor necrosis factor-alpha-and interleukin-1beta-mediated apoptosis by Fas pathway inhibition in human osteoblastic cell line MG-63. Life Sci 2005;77:2964-2976.
34. Kuo PL, Huang YT, Chang CH, et al. Fraxetin inhibits the induction of anti-Fas IgM, tumor necrosis factor-alpha and interleukin-1beta-mediated apoptosis by Fas pathway inhibition in human osteoblastic cell line MG-63. Int Immunopharmacol 2006;6:1167-1175.
35. Do Y, Ryu S, Nagarkatti M, et al. Role of death receptor pathway in estradiol-induced T-cell apoptosis in vivo. Toxicol Sci 2002; 70:63-72.
36. Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun 2005;328:688-696.